- CSL Canada announced that the first Canadian patient has received Hemgenix (etranacogene dezaparvovec), a one-time gene therapy for eligible adults living with hemophilia B, at London Health Sciences Centre in Ontario. The treatment marks the first real-world administration of Hemgenix in Canada outside of a clinical trial.
- Hemgenix is approved for adults with severe to moderately severe hemophilia B who require routine prophylaxis to prevent or reduce bleeding episodes. The therapy works by helping the body produce Factor IX on its own, potentially reducing the long-term burden of ongoing replacement therapy and disease management.
- Following a successful pan-Canadian Pharmaceutical Alliance (pCPA) agreement, Hemgenix is now publicly reimbursed in Ontario and British Columbia through the Exceptional Access Program, while additional provinces continue to evaluate access.
- CSL Canada said the milestone highlights growing collaboration between healthcare systems and clinical teams to bring advanced gene therapies into real-world care settings for Canadians living with rare bleeding disorders.
Takeaways
Hemgenix has moved from theory to practice in Canada, with the first patient now treated outside a trial and public funding in place in Ontario and British Columbia.
Market‑wise, this single‑dose gene therapy starts to shift severe hemophilia B care away from lifelong factor IX prophylaxis toward one‑time, extremely high‑cost interventions negotiated through pCPA and Exceptional Access–type programs, forcing provinces to build new pathways for selecting eligible adults and funding advanced therapies while more gene therapies line up behind it.
Source: Ca Newswire
